

(Nirmatrelvir-Ritonavir) Paxlovid™ Prescription

MUST include accurate medication list with Form

Please fax completed form **AND** patient's medication list to patient's preferred pharmacy

| Prescriber Information | | Patient Information | | | |
|------------------------|-------------|---------------------|-----------|--|---------|
| First Name | Last Name | First Name | Last Name | Sex (at birth) <input type="checkbox"/> Male <input type="checkbox"/> Female | DOB |
| Address | | Address | | Health Card No. . | Version |
| | | City | | Postal Code | |
| City | Postal Code | Telephone | | Preferred Language <input type="checkbox"/> EN <input type="checkbox"/> Other | |
| Telephone | Fax | Height (cm) | | Weight (Kg) | |

INCLUSION CRITERIA: MUST MEET CRITERIA TO PROCEED WITH TREATMENT

Date of positive COVID test: _____ Date of symptom onset (must be 5 days or less): _____

| AGE (YEARS) | NUMBER OF VACCINE DOSES | |
|--|--|-----------------------------------|
| | 0, 1, OR 2 DOSES | 3 DOSES |
| 18 to 59 | <input type="checkbox"/> Eligible if 1 or more risk factors | Not Eligible |
| 60 to 69 | <input type="checkbox"/> Eligible | Not Eligible |
| 70 or greater | <input type="checkbox"/> Eligible | <input type="checkbox"/> Eligible |
| Immunocompromised individuals of any age (18 years of age and older) | <input type="checkbox"/> Eligible: Therapeutics should always be recommended for immunocompromised individuals not expected to mount an adequate immune response to COVID-19 vaccination or SARS-CoV-2 infection due to their underlying immune status, regardless of age or vaccine status. | |
| Pregnancy | 0 DOSES | 1,2, OR 3 DOSES |
| | Eligible | Not Eligible |

Indigenous persons (First Nations, Inuit, or Métis), Black persons, and members of other racialized communities may be at high risk of disease progression due to disparate rates of comorbidity, increased vaccination barriers, and social determinants of health, and should be considered priority populations for access to COVID-19 therapeutics.

Risk Factors: (Check all that apply)

- Obesity (BMI greater than or equal to 30 kg/m²)
 - Diabetes
 - Heart disease, hypertension, congestive heart failure
 - Chronic respiratory disease, including cystic fibrosis
 - Cerebral palsy
 - Intellectual disability
 - Sickle cell disease
 - Moderate or severe kidney disease (eGFR less than 60 ml/min)
 - Moderate or severe liver disease (e.g. Child-Pugh Class B or C)
- * Evidence for less than 18 years of age is limited. Multidisciplinary consultation with infectious diseases and primary care is recommended**

Immunocompromise Factors: (Check all that apply)

- Solid organ or bone marrow transplant (*)
 - CAR T-cell therapy
 - Anti-CD 20 agent
 - Alkylating agents, anti-metabolites (*)
 - Advanced or untreated HIV
 - Congenital immunodeficiency
 - Anti-TNF blockers or other biologic agents (*)
 - Taking chronic oral corticosteroid (greater than 20mg/d prednisone equivalent for greater than 2 weeks)
 - Other: Name of Immune modifying Drug _____
- Note: These individuals should have a reasonable expectation for 1-year survival prior to SARS-COV-2 infection**

(*) Depending on absolute contraindications

(Nirmaltrevir-Ritonavir) Paxlovid™ Assessment:

| | |
|--|--|
| <input type="checkbox"/> Attach current medication, herbal, OTC list | Existing liver impairment: <input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/> UNKNOWN |
| <input type="checkbox"/> Patient's home pharmacy | Existing renal impairment: <input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/> UNKNOWN |
| <input type="checkbox"/> Home pharmacy phone number | If YES, enter Serum Creatinine and eGFR if available |
| <input type="checkbox"/> Allergies <input type="checkbox"/> NKA | <input type="checkbox"/> Serum Creatinine (µmol/L): _____ Date: _____ |
| Is the patient pregnant? <input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/> N/A | <input type="checkbox"/> eGFR (ml/min): _____ Date: _____ |

Note pharmacist will review eligibility, assess drug interactions and confirm dosing prior to releasing the medication. Any recommended changes to the therapeutic regimen will be communicated back to the prescriber.

Medication Order

- Standard Dose (eGFR above 60ml/min)**
- Paxlovid (Nirmatrelvir 150mg and Ritonavir 100mg): Take 2 pink tablets of nirmatrelvir and 1 white tablet of ritonavir once in the morning and once in the evening for 5 days
- Reduced Dose (eGFR between 30-59ml/min)**
- Paxlovid (Nirmatrelvir 150mg and Ritonavir 100mg): Take 1 pink tablet of nirmatrelvir and 1 white tablet of ritonavir once in the morning and once in the evening for 5 days

By prescribing this medication, the referring prescriber assumes responsibility for all follow up.

Physician/NP Registration Number

Signature

Date